Angela Horvath1, Augustinas Bausys2,3,4, Rasa Sabaliauskaite5, Eugenijus Stratilatovas6, Sonata Jarmalaite5, Burkhard Schuetz7, Philipp Stiegler8, Rimantas Bausys6,9, Vanessa Stadlbauer1, Kestutis Strupas9. 1. Department of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria. 2. Department of Abdominal Surgery and Oncology, National Cancer Institute, Vilnius, Lithuania. abpelikanas@gmail.com. 3. Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. abpelikanas@gmail.com. 4. Department of Transplantation Surgery, Medical University of Graz, Graz, Austria. abpelikanas@gmail.com. 5. National Cancer Institute, Vilnius, Lithuania. 6. Department of Abdominal Surgery and Oncology, National Cancer Institute, Vilnius, Lithuania. 7. Biovis Diagnostik, Limburg, Germany. 8. Department of Transplantation Surgery, Medical University of Graz, Graz, Austria. 9. Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Abstract
BACKGROUND: Subtotal gastrectomy with Billroth II reconstruction (SGB2) results in increased gastric pH and diminished gastric barrier. Increased gastric pH following PPI therapy has an impact on the gut microbiome, intestinal inflammation, and possibly patient health. If similar changes are present after SGB2, these can be relevant for patient health and long-term outcomes after surgery. The aim of the study is to investigate whether SGB2 is associated with specific changes in gut microbiome composition and intestinal inflammation. PATIENTS AND METHODS: This cross-sectional proof-of-concept study includes patients after SGB2 (n = 14) for early gastric cancer and their nongastrectomized in-house relatives as controls (n = 8). Fecal microbiome composition, intestinal inflammation (fecal calprotectin), gut permeability (DAO, LBP, sCD14), systemic inflammation (CRP) markers, and gastrointestinal symptoms are investigated. This study is registered at ClinicalTrials.gov (NCT03418428). RESULTS: Microbiome oralization following SGB2 was defined by an increase in Escherichia-Shigella, Enterococcus, Streptococcus, and other typical oral cavity bacteria (Veillonella, Oribacterium, and Mogibacterium) abundance. The fecal calprotectin was increased in the SGB2 group [100.9 (52.1; 292) vs. 25.8 (17; 66.5); p = 0.014], and calprotectin levels positively correlated with the abundance of Streptococcus (rs = 0.639; padj = 0.023). Gastrointestinal symptoms in SGB2 patients were associated with distinct taxonomic changes of the gut microbiome. CONCLUSIONS: SGB2 is associated with oralization of the gut microbiome; intestinal inflammation and microbiome changes were associated with gastrointestinal symptoms. These novel findings may open gut microbiome as a new target for therapy to improve quality of life and general patient health in long-term survivors after SGB2.
BACKGROUND: Subtotal gastrectomy with Billroth II reconstruction (SGB2) results in increased gastric pH and diminished gastric barrier. Increased gastric pH following PPI therapy has an impact on the gut microbiome, intestinal inflammation, and possibly patient health. If similar changes are present after SGB2, these can be relevant for patient health and long-term outcomes after surgery. The aim of the study is to investigate whether SGB2 is associated with specific changes in gut microbiome composition and intestinal inflammation. PATIENTS AND METHODS: This cross-sectional proof-of-concept study includes patients after SGB2 (n = 14) for early gastric cancer and their nongastrectomized in-house relatives as controls (n = 8). Fecal microbiome composition, intestinal inflammation (fecal calprotectin), gut permeability (DAO, LBP, sCD14), systemic inflammation (CRP) markers, and gastrointestinal symptoms are investigated. This study is registered at ClinicalTrials.gov (NCT03418428). RESULTS: Microbiome oralization following SGB2 was defined by an increase in Escherichia-Shigella, Enterococcus, Streptococcus, and other typical oral cavity bacteria (Veillonella, Oribacterium, and Mogibacterium) abundance. The fecal calprotectin was increased in the SGB2 group [100.9 (52.1; 292) vs. 25.8 (17; 66.5); p = 0.014], and calprotectin levels positively correlated with the abundance of Streptococcus (rs = 0.639; padj = 0.023). Gastrointestinal symptoms in SGB2 patients were associated with distinct taxonomic changes of the gut microbiome. CONCLUSIONS: SGB2 is associated with oralization of the gut microbiome; intestinal inflammation and microbiome changes were associated with gastrointestinal symptoms. These novel findings may open gut microbiome as a new target for therapy to improve quality of life and general patient health in long-term survivors after SGB2.
Authors: A G Clooney; C N Bernstein; W D Leslie; K Vagianos; M Sargent; E J Laserna-Mendieta; M J Claesson; L E Targownik Journal: Aliment Pharmacol Ther Date: 2016-02-29 Impact factor: 8.171
Authors: M Carboni; S Guadagni; M A Pistoia; G Amicucci; D Tuscano; P Negro; P L Smith; C L Walters Journal: Scand J Gastroenterol Date: 1986-05 Impact factor: 2.423
Authors: Matthew A Jackson; Julia K Goodrich; Maria-Emanuela Maxan; Daniel E Freedberg; Julian A Abrams; Angela C Poole; Jessica L Sutter; Daphne Welter; Ruth E Ley; Jordana T Bell; Tim D Spector; Claire J Steves Journal: Gut Date: 2015-12-30 Impact factor: 23.059
Authors: Carmen Haro; Oriol A Rangel-Zúñiga; Juan F Alcalá-Díaz; Francisco Gómez-Delgado; Pablo Pérez-Martínez; Javier Delgado-Lista; Gracia M Quintana-Navarro; Blanca B Landa; Juan A Navas-Cortés; Manuel Tena-Sempere; José C Clemente; José López-Miranda; Francisco Pérez-Jiménez; Antonio Camargo Journal: PLoS One Date: 2016-05-26 Impact factor: 3.240
Authors: Samantha Franklin; Samuel L Aitken; Yushi Shi; Pranoti V Sahasrabhojane; Sarah Robinson; Christine B Peterson; Naval Daver; Nadim A Ajami; Dimitrios P Kontoyiannis; Samuel A Shelburne; Jessica Galloway-Peña Journal: Front Cell Infect Microbiol Date: 2022-03-31 Impact factor: 6.073